Prostate Cancer

• Diagnosis, Imaging, Screening
• General Information
• Risk Factors
• Risk Reduction
• Treatment

Prostate Cancer

Diagnosis, Imaging, and Screening

NEWS:

Men More Likely to Get Prostate Cancer Biopsy Following High PSA Test Result

Over-Diagnosing Prostate Cancer?

Prostate cancer screening practices examined

Prostate Cancer Test Questioned

PSA for Screening, Diagnosis, and Management of Prostate Cancer: A Comprehensive Update

Study Discourages Lower Prostate Test Cutoff

Study: Obesity May Hinder Cancer Screening

ARTICLES:

NGC - ACR Appropriateness Criteria™ for pretreatment staging of clinically localized prostate cancer.

JOURNAL ARTICLES:

An elevated PSA, which normalizes, does not exclude the presence of prostate cancer. (Prostate Cancer Prostatic Dis. 2005)

Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study. (Eur Urol. 2005)

[Asymptomatic prostatitis: a frequent cause of raising PSA] (Recenti Prog Med. 2005)

Complexed Prostate Specific Antigen Density is Better Than the Other PSA Derivatives for Detection of Prostate Cancer in Men with Total PSA between 2.5 and 20ng/ml: Results of a Prospective Multicenter Study. (Eur Urol. 2005)

C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. (BJU Int. 2005)

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC). (Can J Urol. 2005)

Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project. (Urology. 2005)

Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). (Eur J Cancer. 2005)

Diagnosis of prostatic inflammation: efficacy of needle biopsies versus tissue blocks. (Urology. 2005)

Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. (BMC Cancer. 2005)

Diffusion-Weighted Imaging of Prostate Cancer. (J Comput Assist Tomogr. 2005)

Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). (Urology. 2005)

Is quadrant biopsy sufficient in men likely to have advanced prostate cancer? Comparison with extended biopsy. (Pathol Oncol Res. 2005)

Is the positive biopsy core percent really predictive of non-organ confined prostate carcinoma? (Arch Esp Urol. 2005)

Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk. (Prostate. 2005)

LONG-TERM EFFECTS OF FINASTERIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS: RESULTS FROM THE PROSTATE CANCER PREVENTION TRIAL. (J Urol. 2005)

Long-term outcome of detectable PSA levels after radical prostatectomy. (Prostate Cancer Prostatic Dis. 2005)

[MRI for troubleshooting detection of prostate cancer] (Rofo. 2005)

Newer imaging modalities to assess tumor in the prostate. (Cancer Control)

Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. (Urology. 2005)

Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. (J Clin Oncol. 2005)

Positron emission tomography and bone metastases. (Semin Nucl Med. 2005)

[Prostate biopsy] (Nippon Rinsho. 2005)

Prostate biopsy: who, how and when. An update. (Can J Urol. 2005)

Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice. (BJU Int. 2005)

Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL. (Urology. 2005)

Prostate cancer: a comparative study of (11)C-choline PET and MR imaging combined with proton MR spectroscopy. (Eur J Nucl Med Mol Imaging. 2005)

Prostate gland volume is a strong predictor of biopsy results in men 70 years or older with prostate-speci fi c antigen levels of 2.0-10.0 ng/mL. (Int J Urol. 2005)

Prostate needle biopsy: 12 vs. 18 cores -- is it necessary? (Urol Int. 2005)

PROSTATE SPECIFIC ANTIGEN LEVELS IN YOUNG ADULTHOOD PREDICT PROSTATE CANCER RISK: RESULTS FROM A COHORT OF BLACK AND WHITE AMERICANS. (J Urol. 2005)

Screening for prostate cancer (European Journal of Cancer 2005)

Screening for prostate cancer. (Eur J Cancer. 2005)

Screening for prostate cancer: updated experience from the Tyrol study. (Can J Urol. 2005)

Screening for prostate cancer: Who and how often? (J Fam Pract. 2005)

Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. (J Urol. 2005)

Should Men With Serum PSA Levels of 4.0 ng/mL or Less Undergo a Prostate Biopsy? (Nat Clin Pract Urol)

Technology review: high-intensity focused ultrasound for prostate cancer. (Can J Urol. 2005)

The association of body mass index and prostate-specific antigen in a population-based study. (Cancer. 2005)

THE PROSTATIC SPECIFIC ANTIGEN ERA IS ALIVE AND WELL: PROSTATIC SPECIFIC ANTIGEN AND BIOCHEMICAL PROGRESSION FOLLOWING RADICAL PROSTATECTOMY. (Journal of Urology 2005)

Total and Percent Free Prostate-Specific Antigen Levels among U.S. Men, 2001-2002 (Cancer Epidemiology Biomarkers & Prevention 2005)

What pretreatment prostate-specific antigen level warrants long-term androgen deprivation? (Int J Radiat Oncol Biol Phys. 2005)

Go to the top